Addex Therapeutics (ADXN) Change in Cash (2019 - 2025)

Addex Therapeutics has disclosed Change in Cash across 7 years of filings, most recently posting $604.8 billion for Q2 2025.

• Change in Cash for Q2 2025 came in at $604.8 billion, down 73.05% year-over-year; the trailing twelve-month figure through Jun 2025 was -$624.1 billion (up 78.07% YoY), and the FY2025 annual result was -$2.0 million, down 182.69% from the prior year.
• Change in Cash came in at $604.8 billion for Q2 2025 at Addex Therapeutics, up from -$556.9 billion in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $2244.6 billion in Q2 2024 to a low of -$2764.5 billion in Q3 2023.
• The 5-year median for Change in Cash is -$3.2 million (2021), against an average of -$168.7 billion.
• Peak annual rise in Change in Cash reached 6956494.28% in 2023, while the deepest fall reached 178140123.19% in 2023.
• Addex Therapeutics' Change in Cash stood at $1.9 million in 2021, then plunged by 823.36% to -$14.0 million in 2022, then soared by 75.18% to -$3.5 million in 2023, then jumped by 82.87% to -$597015.9 in 2024, then jumped by 101305192.64% to $604.8 billion in 2025.
• The last three Change in Cash figures came in at $604.8 billion (Q2 2025), -$556.9 billion (Q1 2025), and -$597015.9 (Q4 2024), per Business Quant data.